Aims: Because practice-based data on the usage of idarucizumab for urgent dabigatran reversal is unavailable, we evaluated the appropriateness of idarucizumab usage, its haemostatic effectiveness and clinical outcomes.
Boehringer has submitted BI 655075 (idarucizumab) for approval of marketing authorisation to the European Medicines Agency (EMA) and Health Canada,...
Although dabigatran has a favorable risk-benefit profile compared with vitamin K antagonist therapy for venous thromboembolism and nonvalvular atrial fibrillation, major bleeding events, including gastrointestinal (GI) bleeding...
Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) for acute ischemic stroke (AIS) is contraindicated in patient taking either Factor Xa inhibitors or direct thrombin inhibitors.
The FDA has granted approval of Praxbind (idarucizumab), from Boehringer Ingelheim, indicated for patients treated with Pradaxa (dabigatran etexilate mesylate),...
The European Commission has licensed Praxbind (idarucizumab), from Boehringer Ingelheim, a treatment to rapidly and specifically reverse the anticoagulant effects...
Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. Despite that, a strong need for antidotes/reversal agents is still reported by several physicians.
Boehringer has submitted a biologics license application (BLA) to the FDA requesting an Accelerated Approval pathway, for the use of...
Results from an interim analysis of the Phase III RE-VERSE AD study demonstrated that 5g of BI 655075 (idarucizumab), from...
In the last decade, DOACs have increasingly become the agent of choice in atrial fibrillation and venous thromboembolism over vitamin K antagonists (VKAs) in most non-pregnant patients due to a favourable safety profile (Zhu et al., 2018).